Skip to content

ResMed

US · RMD #644 by market cap Listed 1970
235.63 -1.25 -0.53%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:01

✦ Quant Ownership Signal how this is computed

Accumulating
  • The number of reporting institutions increased by 8 in the most recent period (2026/Q3).
  • Total institutional ownership rose 2.3 percentage points.

Ownership vs. money flow

Diverging

Institutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
80.73% +2.34pp
Institutions
1,158 +8
As of
2026/Q3 vs. prior period

Holder types

Mutual Fund64.75%
Government Pension Fund6.77%
Public Company3.38%
Hedge Fund2.79%
Private Company1.70%
Sovereign Wealth Fund0.52%
Individual/Insider0.49%
Insurance Company0.30%
Family Office/Trust0.16%
Other19.14%

Top holders as of 2026-09-30

BlackRock 8.90% · 12.52M sh
Vanguard Capital Management, LLC 7.31% · 10.29M sh
Vanguard Portfolio Management, LLC 5.63% · 7.91M sh
State Street Global Advisors 4.88% · 6.86M sh
Australian Super 4.67% · 6.57M sh
Geode Capital Management, LLC 3.14% · 4.42M sh
Walter Scott & Partners Limited 1.87% · 2.63M sh
First Trust Advisors L.P. 1.62% · 2.28M sh
UBS Asset Management 1.53% · 2.15M sh
Invesco Capital Management LLC 1.30% · 1.83M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 13 buys · 37 sells

NameRoleStake
Michael Farrell Chairperson & CEO 0.34%
Peter Farrell Founder, Chair Emeritus & Non-Executive Director 0.04%
Brett Sandercock Advisor 0.04%
Ronald Taylor Lead Independent Non-Executive Director 0.02%
Justin Leong Chief Product Officer 0.02%
Carol Burt Independent Non-Executive Director 0.01%
Richard Sulpizio Former Independent Non-Executive Director 0.01%
Michael Rider Chief Legal Officer 0.01%
Harjit Gill Independent Non-Executive Director 0.01%
Karen Drexler Independent Non-Executive Director 0.01%
Kaushik Ghoshal Former Chief Commercial Officer - SaaS 0.01%
Desney Tan Independent Non-Executive Director 0.00%

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-11-10 Peter Farrell Founder, Chair Emeritus & Non-Executive Director Sale to Issuer -169 $234.11
2026-11-10 Jan De Witte Independent Non-Executive Director Sale to Issuer -59 $234.11
2026-11-10 Harjit Gill Independent Non-Executive Director Sale to Issuer -35 $234.11
2026-11-10 Michael Farrell Chairperson & CEO Sale to Issuer -8,111 $234.11
2026-11-10 Michael Rider Chief Legal Officer Sale to Issuer -1,943 $234.11
2026-11-10 Aaron Bloomer Chief Financial Officer Sale to Issuer -1,095 $234.11
2026-11-08 Michael Farrell Chairperson & CEO Derivative Exercise and Sale -4,993 $146.34–235.35
2026-10-22 Michael Rider Chief Legal Officer Automatic Disposition -400 $255.00
2026-10-06 Michael Farrell Chairperson & CEO Derivative Exercise and Sale -4,991 $146.34–226.33
2026-09-07 Michael Farrell Chairperson & CEO Derivative Exercise and Sale -4,991 $146.34–222.44
2026-09-01 Peter Farrell Founder, Chair Emeritus & Non-Executive Director Automatic Disposition -970 $234.73
2026-08-13 Justin Leong Chief Product Officer Other Acquisition +6,461 --
2026-08-13 Michael Farrell Chairperson & CEO Other Acquisition +13,547 --
2026-08-13 Michael Rider Chief Legal Officer Other Acquisition +3,230 --
2026-08-13 Aaron Bloomer Chief Financial Officer Other Acquisition +9,072 --
2026-08-06 Michael Farrell Chairperson & CEO Derivative Exercise and Sale -4,991 $146.34–205.69
2026-08-04 Peter Farrell Founder, Chair Emeritus & Non-Executive Director Automatic Disposition -8,000 $225.00
2026-07-06 Michael Farrell Chairperson & CEO Derivative Exercise and Sale -4,991 $146.34–218.55
2026-06-07 Michael Farrell Chairperson & CEO Derivative Exercise and Sale -4,991 $146.34–193.96
2026-05-31 Michael Rider Chief Legal Officer Sale to Issuer -268 $190.57

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 20:01:25 · For reference only, not investment advice and not tailored to your situation.

ResMed discussion 0 comments

Add a comment